AtomVie Global Radiopharma Inc.
AtomVie Global Radiopharma, a CPDC spin-off, is a CDMO for the GMP manufacturing and global distribution of clinical and commercial radiotherapeutics.
Leveraging over seven years of expertise in the GMP manufacturing and global distribution of radiotherapeutics, the Centre for Probe Development and Commercialization (CPDC) is launching AtomVie Global Radiopharma Inc. (AtomVie), a global leading Contract Development and Manufacturing Organization (CDMO). AtomVie offers the full range of scientific, technical, regulatory, quality, logistics and business expertise combined with a specialized infrastructure for the development of your radiotherapeutics from Phase 1 to the commercial marketplace. AtomVie has in-depth experience in radiopharmaceutical manufacturing, including expertise in radiolabeling with an array of radioisotopes such as Lu-177, Ac-225, I-131 and ligands that range from small molecules, to peptides to small and large antibodies. In partnership with Isotopia, AtomVie produces Lu-177 (n.c.a.) from its own facility, offering a unique value proposition to its clients with Lu-177-based programs. We are building a state-of-the-art, multi-product 37,000 sq ft facility that will be operational in 2024. AtomVie is the CDMO of choice to address your needs for your radiotherapeutics.
Brands: AtomVie Global Radiopharma offers the complete suite of capabilities, including the following:
• Analytical and process development
• Scale-up & stability studies
• Analytical and process validation
• Logistics to global destinations (North America, EU, Asia and more)
• Regulatory affairs (FDA, Health Canada and EMA)
• Routine clinical and commercial supply to meet the needs of our clients
• Supply of GMP-grade Lu-177 (n.c.a.)